Novocure (NASDAQ: NVCR) delivered a solid first-quarter performance, beating revenue expectations and moving closer to profitability as its commercial and clinical pipelines gain momentum. The company reported total net revenues of $174.1 million for the quarter ended March 31, 2026, a 12% increase year-over-year and ahead of the analyst consensus estimate of $171.2 million.
Despite the revenue beat, the company posted a net loss of $71.1 million, or $0.62 per share, which was wider than the $0.52 per share loss analysts had anticipated. However, a significant portion of that loss was driven by a one-time $43 million non-cash share-based compensation charge triggered by the FDA approval of Optune Pax in February. Stripping out these and other items, adjusted EBITDA came in at -$0.3 million, a major improvement from the -$5.0 million reported in the same quarter last year.
The market reacted favorably to the news, with shares climbing roughly 9% in pre-market trading following the release. This positive price action suggests investors are looking past the wider GAAP loss and focusing on the underlying revenue growth, improving margins, and the string of regulatory and clinical milestones achieved during the quarter.
Revenue Breakdown and Growth Drivers
Revenue growth was broad-based, with key markets all contributing to the top line:
Total active patients on TTFields therapy grew to 4,791 globally, up 12% year-over-year. The core Optune Gio franchise, used primarily in glioblastoma (GBM), added 9% more patients compared to the same period last year, with particular strength in international markets like Germany and Japan.
Beyond the core GBM business, the newer product launches are starting to contribute meaningfully:
- Optune Lua (non-small cell lung cancer): Generated $3.1 million in recognized revenue, with active patient count surging 56% year-over-year to 165 patients. Japan's recent approval of National Health Insurance reimbursement in March should accelerate adoption.
- Optune Pax (pancreatic cancer): Received 169 prescriptions in the quarter, with 83 active patients on therapy by March 31. This product was only approved by the FDA in February 2026, making this a very early-stage launch.
Gross margin improved to 78% from 75% in the prior year, driven by lower array costs from better utilization and reduced supplier pricing. This margin expansion, combined with topline growth, is a key reason the company is approaching EBITDA breakeven.
Outlook and Guidance
Novocure management raised its full-year 2026 revenue guidance to between $690 million and $710 million, up from the prior range of $675 million to $705 million. The midpoint of this updated range sits at $700 million, which is in line with the analyst consensus of approximately $706 million.
The company also narrowed its adjusted EBITDA guidance to a range of negative $15 million to $0 million (from negative $20 million to $0 million previously), signaling that management expects to be at or near breakeven by year-end.
Management noted that full-year guidance assumes:
- Mid-single digit net revenue growth from Optune Gio
- Combined revenue from Optune Lua and Optune Pax between $15 million and $25 million
- Gross margins in the mid-70% range
- Foreign exchange rates as of March 31, 2026
Clinical and Regulatory Catalysts Ahead
The company has several important upcoming catalysts that could drive further upside:
- Topline data from the Phase 3 TRIDENT trial in newly diagnosed GBM (expected Q2 2026)
- FDA decision on the premarket approval application for TTFields in brain metastases from NSCLC (Q4 2026)
- Completion of enrollment in the Phase 3 KEYNOTE D58 trial in newly diagnosed GBM (Q4 2026)
Additionally, positive topline results from the Phase 2 PANOVA-4 trial in metastatic pancreatic cancer were announced in March, showing a statistically significant improvement in disease control rate compared to historical controls. This de-risks the pipeline and could support future label expansions.
Segment Performance Overview
For context, here are the key operational metrics from the quarter:
Optune Gio (GBM)
- Active patients: 4,543 (up 9% YoY)
- U.S. patients: 2,250
- Top international markets: France (503), Japan (535), Germany (641)
Optune Lua (Lung Cancer)
- Active patients: 165 (up 56% YoY)
- U.S. patients: 106
Optune Pax (Pancreatic Cancer)
- Prescriptions received: 169
- Active patients: 83 (all U.S.)
Financial Position
The company ended the quarter with $432.0 million in cash, cash equivalents, and short-term investments, providing ample runway to fund ongoing clinical trials and commercialization efforts.
For more detailed historical earnings data and forward-looking analyst estimates, visit Novocure's earnings page and analyst ratings page to track performance and projections over time.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Always conduct your own research or consult with a licensed financial advisor before making any investment decisions.